Tenosynovial Giant Cell Tumor (TGCT) Real-World Participant Experience With Vimseltinib

Recruiting

• Conditions: Tenosynovial Giant Cell Tumor

• Registration Number: NCT07075471
• Lead Sponsor: Deciphera Pharmaceuticals, LLC

Brief Summary

The goal of this observational study is to better understand real-world use of vimseltinib, treatment patterns, and health-related quality of life in participants treated with vimseltinib for TGCT.

This study will collect data in an observational disease registry involving no intervention to the participants and will not influence standard medical care or impact treatment decisions for participants.

Detailed Description

Not available

Study Timeline

• Study First Submitted: 2025-07-11
• Study First Submitted QC: 2025-07-11
• Study First Posted: 2025-07-20
• Status Verified: 2025-08
• Study Start: 2025-08-01
• Last Update Submitted: 2025-08-01
• Last Update Posted: 2025-08-06
• Primary Completion: 2027-09
• Study Completion: 2027-09-01

Recruitment & Eligibility

• Status: RECRUITING
• Sex: All
• Target Recruitment: 100

Inclusion Criteria

1. Diagnosis of TGCT according to medical records
2. Prescribed vimseltinib per the approved label requirements. Participants are eligible if either (A) the decision to receive vimseltinib has been made but treatment has not yet been initiated or (B) the decision to receive vimseltinib has been made and participant has received first dose of prescribed vimseltinib less than 6 months prior to study enrollment
3. Has provided informed consent and medical records release

Exclusion Criteria

1. Participant has received any other systemic agent for the treatment of TGCT during the 6 months prior to starting treatment with vimseltinib
2. Participant has received the first dose of prescribed vimseltinib in the current treatment course more than 6 months before study enrollment
3. Participant is active in an interventional clinical trial of vimseltinib

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Duration of Vimseltinib Treatment	Baseline up to 12 months
Time to Discontinuation of Vimseltinib	Baseline to Discontinuation (Estimated up to 12 months)

Trial Locations

Locations (1)

Synexus Clinical Research, US INC; 🇺🇸 Wilmington, North Carolina, United States